Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Targeting melanoma's MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors.
Nat Commun. 2019 Nov 14;10(1):5167. doi: 10.1038/s41467-019-12409-w.
Nat Commun. 2019.
PMID: 31727888
Free PMC article.
Dual-Mechanism ERK1/2 Inhibitors Exploit a Distinct Binding Mode to Block Phosphorylation and Nuclear Accumulation of ERK1/2.
Kidger AM, Munck JM, Saini HK, Balmanno K, Minihane E, Courtin A, Graham B, O'Reilly M, Odle R, Cook SJ.
Kidger AM, et al. Among authors: minihane e.
Mol Cancer Ther. 2020 Feb;19(2):525-539. doi: 10.1158/1535-7163.MCT-19-0505. Epub 2019 Nov 20.
Mol Cancer Ther. 2020.
PMID: 31748345
Item in Clipboard
Steroid-free combination of 5-azacytidine and venetoclax for the treatment of multiple myeloma.
Flanagan L, Coughlan A, Cosgrove N, Roe A, Wang Y, Gilmore S, Drozdz I, Comerford C, Ryan J, Minihane E, Parvin S, O'Dwyer M, Quinn J, Murphy P, Furney S, Glavey S, Chonghaile TN; Leukemia Research Foundation; Science Foundation Ireland; Breakthrough Cancer Research.
Flanagan L, et al. Among authors: minihane e.
Haematologica. 2024 Mar 21. doi: 10.3324/haematol.2023.283771. Online ahead of print.
Haematologica. 2024.
PMID: 38511268
Free article.
Item in Clipboard
Cite
Cite